Although anti-IL-5 and anti-IL-5Rα agents did not reduce FeNO in all patients with severe asthma, recent evidence suggested that anti-IL-5 agents can reduce FeNO levels, and that responders to the agents were more likely to achieve clinical remission after 12 months (27). This evidence concerns the gene IL5 and asthma.